system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, METHODS, RESULTS. Meshes: Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Cadherins, Carboplatin, Carcinoma, Non-Small-Cell Lung, Clinical Trials, Phase II as Topic, Enzyme-Linked Immunosorbent Assay, Female, Follow-Up Studies, Humans, Immunoglobulins, Intravenous, Insulin, Insulin-Like Growth Factor Binding Protein 1, Insulin-Like Growth Factor I, Lung Neoplasms, Male, Middle Aged, Multicenter Studies as Topic, Neoplasm Staging, Paclitaxel, Randomized Controlled Trials as Topic, Survival Rate, Treatment Outcome.
user
Do pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab? Context: Phase III trials of the anti-insulin-like growth factor type 1 receptor (IGF-IR) antibody figitumumab (F) in unselected non-small-cell lung cancer (NSCLC) patients were recently discontinued owing to futility. Here, we investigated a role of free IGF-1 (fIGF-1) as a potential predictive biomarker of clinical benefit from F treatment. Pre-treatment circulating levels of fIGF-1 were tested in 110 advanced NSCLC patients enrolled in a phase II study of paclitaxel and carboplatin given alone (PC) or in combination with F at doses of 10 or 20 mg kg(-1) (PCF10, PCF20). Cox proportional hazards model interactions were between 2.5 and 3.5 for fIGF-1 criteria in the 0.5-0.9 ng ml(-1) range. Patients above each criterion had a substantial improvement in progression-free survival on PCF20 related to PC alone. Free IGF-1 correlated inversely with IGF binding protein 1 (IGFBP-1, ρ=-0.295, P=0.005), and the pre-treatment ratio of insulin to IGFBP-1 was also predictive of F clinical benefit. In addition, fIGF-1 levels correlated with tumour vimentin expression (ρ=0.594, P=0.021) and inversely with E-cadherin (ρ=-0.389, P=0.152), suggesting a role for fIGF-1 in tumour de-differentiation.
assistant
Free IGF-1 may contribute to the identification of a subset of NSCLC patients who benefit from F therapy. Final Decision: yes